Chemistry:Cetilistat
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C25H39NO3 |
| Molar mass | 401.591 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Cetilistat is a drug designed to treat obesity. It acts in the same way as the older drug orlistat (Xenical) by inhibiting pancreatic lipase, an enzyme that breaks down triglycerides in the intestine. Without this enzyme, triglycerides from the diet are prevented from being hydrolyzed into absorbable free fatty acids and are excreted undigested.[1]
In human trials from 2007, cetilistat was shown to produce similar weight loss to orlistat, but also produced similar side effects such as oily, loose stools, fecal incontinence, frequent bowel movements, and flatulence.[2][3] It is likely that the same precautions would apply in that absorption of fat-soluble vitamins and other fat-soluble nutrients may be inhibited, requiring vitamin supplements to be used to avoid deficiencies.
Cetilistat completed Phase 1 and 2 trials in the West and as of 2009 was in Phase 3 trials in Japan where it was partnered with Takeda.[4] Norgine BV acquired the full global rights to cetilistat from Alizyme after the latter went into administration.[5][needs update]
In 2010, a phase 2 trial found cetilistat significantly reduced weight and was better tolerated than orlistat.[6]
Takeda gained approval to market Cetilistat in Japan, but terminated the license agreement with Norgine in 2018. [7]
See also
- Anti-obesity medication
References
- ↑ "Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats". Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et Metabolisme 40 (8): 539–543. August 2008. doi:10.1055/s-2008-1076699. PMID 18500680.
- ↑ "Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients". International Journal of Obesity 31 (3): 494–499. March 2007. doi:10.1038/sj.ijo.0803446. PMID 16953261.
- ↑ "Cetilistat, a new lipase inhibitor for the treatment of obesity". Current Opinion in Investigational Drugs 9 (4): 414–421. April 2008. PMID 18393108.
- ↑ "Alizyme - Cetilistat". http://www.alizyme.com/alizyme/products/cetilistat/.
- ↑ "Norgine acquires cetilistat". http://www.norgine.com/downloads/pr_archive/Norgine%20aquires%20cetilistat_2.pdf.
- ↑ "Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical)". Obesity 18 (1): 108–115. January 2010. doi:10.1038/oby.2009.155. PMID 19461584.
- ↑ "Takeda and Norgine terminate obesity drug deal". https://norgine.com/press_release/termination-of-license-and-development-agreement-for-oblean-tablets-120mg-for-treatment-of-obesity/.
 |  |
